Laura Chico

“I guess just one, and I don't know if I should direct this towards Eric a little bit, but I'm trying to better understand what is the capacity of these centers to treat?”

“I guess one, just follow up there, Eric, if I'm doing the math right, I think the new guidance for IBSRELA implies about a 30% increase in the second half over the first half.”

“I'm wondering if you could expand a little bit further. what capacity do the centers have for switch patients? Just wondering if there's any additional considerations that the physicians need to work through for a switch patient versus perhaps somebody that's new to treatment.”

“One, it looks like a very solid Orlodeo performance this quarter.”

“One area of concern we've heard from physicians is being in a challenging spot. So, if they get peer pushback on combining something like Silspari and an April inhibitor, they might have to make a tough decision on which one to take over cost considerations.”